Products

Resources

Support

Shop

Products

Resources

Support

Shop

Pioneers and global leaders in medical cannabis research
Pioneers and global leaders in medical cannabis research
Pioneers and global leaders in medical cannabis research
Pioneers and global leaders in medical cannabis research

20+

Years of leadership

Two decades driving medical cannabis research and patient care.

17

Peer-reviewed studies

Published evidence shaping global medical cannabis science.

20,000+

Patient feedback records

Clinical insights from one of the world’s largest datasets.

7

Clinical trials

Strain-specific, double-blind trials setting new standards.

Tikun Olam’s Clinical Research Library

Tikun Olam’s Clinical Research Library

With over two decades of clinical research and more than 20,000 patient records, our library combines peer-reviewed studies, clinical trials, and real-world outcomes. Explore the evidence that shapes our formulas and demonstrates measurable patient results.

Crohn’s Disease 1

Crohn’s Disease 1

Crohn’s Disease 1

Crohn’s Disease 1

Treatment of Crohn's Disease with Cannabis: 

An Observational Study


The Israel Medical Association Journal, 2011

A retrospective study that observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).

STUDY POPULATION:

30 Patients 

STRAIN USED: 

Erez

KEYRESULTS:

  • 21 of the 30 patients improved significantly with cannabis treatment.

  • The average Harvey Bradshaw Index improved from 14 to 17; the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications.

  • The mean number of bowel movements decreased from 8 to 5 per day.

  • The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4.

  • Only 2 of 15 patients who had surgery prior to cannabis treatment needed additional surgery during treatment.

  • 18.1% of patients stopped using opioid analgesics or reduced their dose.

Treatment of Crohn's Disease with Cannabis: 

An Observational Study


The Israel Medical Association Journal, 2011

A retrospective study that observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).

STUDY POPULATION:

30 Patients 

STRAIN USED: 

Erez

KEYRESULTS:

  • 21 of the 30 patients improved significantly with cannabis treatment.

  • The average Harvey Bradshaw Index improved from 14 to 17; the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications.

  • The mean number of bowel movements decreased from 8 to 5 per day.

  • The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4.

  • Only 2 of 15 patients who had surgery prior to cannabis treatment needed additional surgery during treatment.

  • 18.1% of patients stopped using opioid analgesics or reduced their dose.

Treatment of Crohn's Disease with Cannabis: 

An Observational Study


The Israel Medical Association Journal, 2011

A retrospective study that observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).

STUDY POPULATION:

30 Patients 

STRAIN USED: 

Erez

KEYRESULTS:

  • 21 of the 30 patients improved significantly with cannabis treatment.

  • The average Harvey Bradshaw Index improved from 14 to 17; the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications.

  • The mean number of bowel movements decreased from 8 to 5 per day.

  • The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4.

  • Only 2 of 15 patients who had surgery prior to cannabis treatment needed additional surgery during treatment.

  • 18.1% of patients stopped using opioid analgesics or reduced their dose.

Treatment of Crohn's Disease with Cannabis: 

An Observational Study


The Israel Medical Association Journal, 2011

A retrospective study that observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).

STUDY POPULATION:

30 Patients 

STRAIN USED: 

Erez

KEYRESULTS:

  • 21 of the 30 patients improved significantly with cannabis treatment.

  • The average Harvey Bradshaw Index improved from 14 to 17; the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications.

  • The mean number of bowel movements decreased from 8 to 5 per day.

  • The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4.

  • Only 2 of 15 patients who had surgery prior to cannabis treatment needed additional surgery during treatment.

  • 18.1% of patients stopped using opioid analgesics or reduced their dose.

Research

menu

Research

menu

Research

menu

Research

menu

Get the full Tikun Olam Medical Research Book

Get the full Tikun Olam Medical Research Book

Get the full Tikun Olam Medical Research Book

Enter your email to download the complete collection of peer-reviewed studies, clinical trials, and patient outcomes that shaped our formulas.

By creating an account using email, I agree to the Terms & Conditions, and acknowledge the Privacy Policy.

Our heirloom cannabis strains

Our heirloom cannabis strains

Our heirloom cannabis strains

The foundation of Tikun Olam is our clinical research and proprietary strains developed in Israel with leading scientists and physicians. Documented in peer-reviewed studies and informed by our own dataset of 20,000+ patient records, these genetics are central to our formulas. Standardized with precise THC:CBD ratios and strain-specific terpenes, we deliver consistent, measurable outcomes across every product.

Avidekel strain:


Cannabinoids: THC <1% | CBD 14-18%


Terpenes: Myrcene, Alpha-pinene, Limonene


Type: Sativa


Clinical Research: Autism, PTSD, Chron’s / Colitis, Migraines, Epilepsy, Fibromyalgia

Avidekel is a sativa-dominant strain developed in close collaboration with Dr. Raphael Mechoulem. High levels of CBD and minimal THC promote a therapeutic experience with little to no psychoactive effects. Avidekel has emerged as a source of relief for patients worldwide, spanning pediatric to geriatric populations, and is regarded as one of the world’s most heavily researched cannabis strains.

Featured in formulas: P1 N1 S1

Erez strain:


Cannabinoids: THC 20%-24% | CBD < 1%


Terpenes: Beta-pinene, Alpha-pinene, Limonene


Type: Indica


Clinical Research: Insomnia, PTSD, Cancer, ALS, Muscle Spasms, Chronic Pain

Erez is an indica-dominant strain, named after Tikun Olam’s first patient in Israel. In the world’s first randomized, placebo-controlled, double-blind cannabis study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results: 45% of Crohn’s patients achieved “complete remission” and over 90% achieved substantial improvement – with no side effects witnessed.

Featured in formulas: P1 G1 S1

Tikun Olam’s Clinical Research Library

With over two decades of clinical research and more than 20,000 patient records, our library combines peer-reviewed studies, clinical trials, and real-world outcomes. Explore the evidence that shapes our formulas and demonstrates measurable patient results.

Crohn’s Disease 1

Research

menu

Treatment of Crohn's Disease with Cannabis: 

An Observational Study


The Israel Medical Association Journal, 2011

A retrospective study that observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).

STUDY POPULATION:

30 Patients 

STRAIN USED: 

Erez

KEYRESULTS:

  • 21 of the 30 patients improved significantly with cannabis treatment.

  • The average Harvey Bradshaw Index improved from 14 to 17; the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications.

  • The mean number of bowel movements decreased from 8 to 5 per day.

  • The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4.

  • Only 2 of 15 patients who had surgery prior to cannabis treatment needed additional surgery during treatment.

  • 18.1% of patients stopped using opioid analgesics or reduced their dose.

Treatment of Crohn's Disease with Cannabis: 

An Observational Study


The Israel Medical Association Journal, 2011

A retrospective study that observed cannabis as treatment for Crohn’s Disease and found that cannabis use resulted in significant positive effects on the symptoms of the disease (number of bowel movements, quality of bowel activity, abdominal pain, and other complications).

STUDY POPULATION:

30 Patients 

STRAIN USED: 

Erez

KEYRESULTS:

  • 21 of the 30 patients improved significantly with cannabis treatment.

  • The average Harvey Bradshaw Index improved from 14 to 17; the index measures general well-being, abdominal pain, number of liquid stools per day, abdominal mass, and related complications.

  • The mean number of bowel movements decreased from 8 to 5 per day.

  • The need for other medication was significantly reduced; most notably, the number of patients needing steroid treatment reduced from 26 to 4.

  • Only 2 of 15 patients who had surgery prior to cannabis treatment needed additional surgery during treatment.

  • 18.1% of patients stopped using opioid analgesics or reduced their dose.

Join to be
first to know

Join to be
first to know

Join to be
first to know

Be first to get early access to insights, physician tips, events, and product updates.

By creating an account using email, I agree to the Terms & Conditions, and acknowledge the Privacy Policy.

FAQ

FAQ

We are the world’s first licensed medical cannabis company (Israel, 2007) with over two decades of clinical research and more than 20,000 patient treatment records. Every formula is standardized for consistency, safety, and predictable relief.

About

Shop

Find a dispensary

Contact

Research

Medical Advisory Board

FAQs

Privacy Policy

Terms of Use

Accessibility

These statements have not been evaluated by the FDA. Tikun Olam products are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before use.

GOVERNMENT WARNING: THIS WEBSITE DISCUSSES CANNABIS PRODUCTS. KEEP OUT OF REACH OF CHILDREN AND ANIMALS. CANNABIS PRODUCTS MAY ONLY BE POSSESSED OR CONSUMED BY PERSONS 21 YEARS OF AGE OR OLDER UNLESS THE PERSON IS A QUALIFIED PATIENT. THE INTOXICATING EFFECTS OF CANNABIS PRODUCTS MAY BE DELAYED UP TO TWO HOURS. CANNABIS USE WHILE PREGNANT OR BREASTFEEDING MAY BE HARMFUL. CONSUMPTION OF CANNABIS PRODUCTS IMPAIRS YOUR ABILITY TO DRIVE AND OPERATE MACHINERY. PLEASE USE EXTREME CAUTION.

Proposition 65 WARNING: This site may reference products that can expose you to cannabis smoke and Δ9-THC, chemicals known to the State of California to cause cancer and birth defects or other reproductive harm. For more information, visit P65Warnings.ca.gov/cannabis.

No sales on this site. Products are available only at licensed California dispensaries. You must be 21+ (or 18+ with a valid physician recommendation) to view product information.

Responsible licensee/advertiser: Tikun Olam LLC • Distribution License C11-0000181-LIC • Manufacturing License CDPH-10003257

Copyright © 2025 Tikun Olam LLC. All rights reserved.